Securities code: Pharmaron Beijing Co.Ltd(300759) securities abbreviation: Pharmaron Beijing Co.Ltd(300759) Announcement No.: 2022014 Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd
2021 annual performance express
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special note: the financial data of 2021 contained in this announcement is only preliminary accounting data, which has not been audited by an accounting firm, and may be different from the final data disclosed in the 2021 annual report. Investors are reminded to pay attention to investment risks.
Except for the adjusted net profit attributable to shareholders of listed companies not under IFRS or otherwise noted, the financial data contained in this performance express are prepared in accordance with the Chinese accounting standards for business enterprises.
1、 Main financial data and indicators in 2021
Unit: RMB 10000
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 7443769751335968 45.00
Operating profit 1914337313238346 44.61
Total profit 1910995513193695 44.84
Net profit attributable to shareholders of listed company 1661028611723824 41.68
Net profit attributable to shareholders of the company in 134080238006803 67.46 city after deducting non recurring profits and losses
Adjusted net profit attributable to shareholders of listed companies under non IFRS 1461984410640292 37.40
Basic earnings per share (yuan) 2.0982 1.482541.53
The weighted average return on net assets was 17.31% and 14.13%, an increase of 3.18 percentage points
Increase / decrease range at the end of the reporting period (%)
Total assets 183891244119087927 54.42
Owner’s rights attributable to shareholders of listed companies 10129240988703199 14.19 profit
Share capital 79417717943875 -0.03
Net capital per share attributable to shareholders of listed company 12.75 11.17 14.15 yuan
Note: 1. The data in this table is the data of the company’s consolidated statements;
2. Unless otherwise specified, the above units are RMB 10000 yuan.
2、 Description of operating performance and financial status
(I) operating performance
During the reporting period, the company achieved a total operating income of 74437697 million yuan, an increase of 45.00% over the same period last year; The operating profit was 1914337300 yuan, an increase of 44.61% over the same period last year; The net profit attributable to the shareholders of the listed company was 1661028600 yuan, an increase of 41.68% over the same period last year; The net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was 1340802300 yuan, an increase of 67.46% over the same period last year; The adjusted net profit attributable to shareholders of listed companies under non IFRS was 14619844 million yuan, an increase of 37.40% over the same period last year.
During the reporting period, all service modules achieved rapid growth, of which the operating revenue of laboratory services was 4565801600 yuan, an increase of 41.09% over the same period last year; CMC (small molecule cdmo) service achieved an operating revenue of 1746167500 yuan, an increase of 42.90% over the same period last year; The operating revenue of clinical research services was 956357700 yuan, an increase of 51.96% over the same period last year; Macromolecules, cells and gene therapy services achieved an operating revenue of 1509665 million yuan, an increase of 466.58% over the same period last year.
(II) financial status
During the reporting period, in addition to the increase of net profit, the net fund raised by H-share convertible bonds received by the company was about RMB 37760407 million. At the same time, it continued to invest in the construction of various projects as planned, and the business scale continued to expand. The total assets of the company increased by 54.42% from RMB 11908792700 at the beginning of the reporting period to RMB 183891244 million at the end of the reporting period.
At the end of the reporting period, the owner’s equity attributable to the shareholders of the listed company was 101292499 million yuan, an increase of 14.19% over the beginning of the period; The share capital at the end of the reporting period was 794177100 yuan, slightly lower than that at the beginning of the period; At the end of the reporting period, the net assets per share attributable to the shareholders of the listed company was 12.75 yuan, an increase of 14.15% over the beginning of the period.
(III) main factors affecting operating performance
During the reporting period, the company further improved the R & D and production service system of small molecule drugs throughout the whole process of drug discovery, preclinical, clinical development and commercialization by deepening the coordination of business in both vertical and horizontal directions; And actively expand the macromolecule, cell and gene therapy service platform, and strive to become a global leader in the integrated service of the whole process of multi therapy drug R & D, so as to promote the company’s market position.
While deepening the international market and strengthening the cooperative relationship with existing large international pharmaceutical companies and biotechnology companies, the company vigorously develops the Chinese market, implements the market strategy more in line with the Chinese market and develops more new customers. With the growth of order quantity and business scale, the company’s operating revenue increased significantly during the reporting period. Under the income growth, the scale effect was further enhanced, and the company’s operating profit, total profit, net profit attributable to shareholders of listed companies, net profit attributable to shareholders of listed companies after deducting non recurring profits and losses, adjusted net profit attributable to shareholders of listed companies under non IFRS and basic earnings per share all achieved significant improvement. Looking forward to 2022, all business segments will continue the development momentum of 2021 under the sustained strong customer demand, the improvement of service capacity, and the expansion of R & D team and production capacity.
3、 Description of the difference from the previous performance forecast
The operating performance disclosed in this performance express is consistent with the expected performance data in the annual performance forecast for 2021 disclosed on cninfo.com on January 22, 2022, and there is no significant difference.
4、 Other instructions
This performance express is the result of the preliminary calculation of the company’s financial department. It has not been audited by the audit institution. The specific financial data will be disclosed in detail in the 2021 annual report. Please make careful decisions and pay attention to investment risks.
5、 Documents for future reference
1. Comparative balance sheet and income statement signed and sealed by the current legal representative of the company, the person in charge of accounting and the person in charge of accounting organization (Accounting Supervisor);
2. Other documents required by SZSE.
Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd. board of directors March 11, 2022
